Gamma Aminobutyric Acid (Gaba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS), counterbalancing excitatory glutamate signaling to maintain the excitation–inhibition (E/I) balance essential for normal brain function. Approximately 20–30% of all CNS neurons are GABAergic, including diverse populations of interneurons that regulate cortical and subcortical circuit activity [1]. [2]
Disruption of GABAergic neurotransmission is increasingly recognized as a key contributor to [neurodegenerative diseases, including alzheimers, huntington-pathway, parkinsons, and als. In alzheimers, the selective vulnerability of specific GABAergic interneuron subtypes—particularly somatostatin-positive (SST) interneurons—leads to network hyperexcitability, impaired oscillatory rhythms, and cognitive decline. Understanding the roles of GABA in health and disease has opened new avenues for therapeutic intervention in neurodegeneration [2:1]. [3]
GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD), which exists in two isoforms: [4]
Both GAD isoforms require pyridoxal 5′-phosphate (PLP, a vitamin B6 derivative) as a cofactor. Dysregulation of GAD expression and activity has been documented in multiple neurodegenerative diseases, with reduced GAD67 mRNA levels observed in the hippocampus and cortex of alzheimers patients [3:1]. [5]
After synthesis, GABA is loaded into synaptic vesicles by the vesicular GABA transporter (VGAT/SLC32A1), also known as vesicular inhibitory amino acid transporter (VIAAT). Upon arrival of an action potential and calcium influx, GABA is released into the synaptic cleft, where it binds to postsynaptic and presynaptic receptors. [6]
GABA is cleared from the synaptic cleft primarily by membrane-bound GABA transporters (GATs), of which four subtypes exist (GAT-1 to GAT-3, and BGT-1). GAT-1, expressed on both neurons and astrocytes, is the most abundant. Tiagabine, a GAT-1 inhibitor, is used clinically as an antiepileptic drug. [7]
Once taken up by astrocytes, GABA is catabolized by GABA transaminase (GABA-T) to succinic semialdehyde, which is further converted to succinate and enters the tricarboxylic acid (TCA) cycle. This metabolic pathway, known as the GABA shunt, links inhibitory neurotransmission to cellular energy metabolism. [8]
Notably, reactive astrocytes in alzheimers overexpress monoamine oxidase B (MAO-B), which produces GABA through an alternative pathway involving putrescine degradation. This astrocytic GABA release has been shown to tonically inhibit surrounding neurons, contributing to memory impairment in AD mouse models [4:1].
GABA exerts its effects through three receptor classes:
GABA_A receptors are ligand-gated chloride channels composed of pentameric subunit assemblies drawn from 19 subunit genes (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3). The most common synaptic configuration is α1β2γ2, while extrasynaptic receptors (e.g., α5βγ2 or α4βδ) mediate tonic inhibition.
Key features in neurodegeneration:
GABA_B receptors are G protein-coupled receptors (Gi/Go) that form obligate heterodimers of GABA_B1 and GABA_B2 subunits. They mediate slow, prolonged inhibition by:
GABA_B receptors are implicated in multiple neurodegenerative conditions. In AD, GABA_B receptor dysfunction contributes to network hyperexcitability and has been proposed as a therapeutic target [6:1]. Baclofen, a GABA_B agonist, has shown neuroprotective properties in preclinical models of neurodegeneration.
Now reclassified as ρ-containing GABA_A receptors, these are primarily expressed in the retina and have limited involvement in neurodegenerative disease.
GABAergic interneurons represent approximately 20% of cortical neurons and are classified into molecularly and functionally distinct subtypes:
PV interneurons are fast-spiking cells that provide perisomatic inhibition to pyramidal neurons, generating gamma oscillations (30–100 Hz) critical for working memory and attention. They include basket cells and chandelier (axo-axonic) cells. PV interneurons are ensheathed by perineuronal nets (PNNs), specialized extracellular matrix structures that provide neuroprotection.
In AD, PV interneurons show relative resilience compared to other interneuron subtypes, potentially due to PNN protection. However, PV interneuron hyperactivity in the subiculum has been shown to drive early amyloid pathology and cognitive deficits [7:1]. Compensatory neuroplasticity in PV interneurons may help maintain executive function in early disease stages [8:1].
SST interneurons target the dendrites of pyramidal neurons, providing dendritic inhibition that modulates excitatory input integration and theta oscillations (4–12 Hz). They are the most vulnerable interneuron subtype in AD, exhibiting tau] inclusions, atrophy, and neuronal loss early in disease progression [9].
SST interneuron loss contributes to:
VIP interneurons are disinhibitory cells that primarily inhibit other interneurons (SST and PV cells), thereby modulating cortical gain and state-dependent processing. Their role in neurodegeneration is less well characterized but is an area of active investigation.
NPY-expressing interneurons overlap with SST-expressing populations and are reduced in AD cortex. CCK interneurons are basket cells that provide perisomatic inhibition at cannabinoid receptor type 1 (CB1)-expressing synapses.
The relationship between GABAergic dysfunction and AD is multifaceted:
Excitation/Inhibition Imbalance: Loss of GABAergic interneurons and altered GABA receptor expression disrupts the E/I balance, producing network hyperexcitability. This manifests clinically as subclinical epileptiform activity, which occurs in 22–54% of AD patients and accelerates cognitive decline [10].
Oscillatory Disruption: Impaired gamma and theta oscillations due to interneuron dysfunction compromise memory encoding and retrieval. Gamma entrainment using 40 Hz sensory stimulation has emerged as a novel therapeutic approach, promoting microglia-mediated amyloid clearance and restoring neural oscillations [11].
Huntington's disease (HD) is characterized by progressive loss of medium spiny neurons (MSNs) in the striatum, the primary GABAergic output of the basal ganglia. These MSNs, which express GABA and substance P or enkephalin, are particularly vulnerable to mutant huntingtin-protein toxicity. This differential vulnerability produces the characteristic choreiform movements of HD [12].
Mutant huntingtin-protein disrupts GABAergic neurotransmission through:
In parkinsons, loss of dopamine input to the striatum disrupts the balance between direct and indirect basal ganglia pathways, both of which involve GABAergic transmission from the striatum. The resulting disinhibition of the subthalamic nucleus and excessive output from the globus pallidus internus/substantia-nigra pars reticulata produces the bradykinesia and rigidity characteristic of PD.
GABAergic dysfunction in PD also involves:
Cortical hyperexcitability is an early feature of als, attributed in part to loss of GABAergic inhibition. Reduced cortical GABA levels, measured by magnetic resonance spectroscopy, correlate with disease progression and clinical disability.
GABA levels can be measured non-invasively using magnetic resonance spectroscopy (MRS), specifically the MEGA-PRESS (Mescher-Garwood Point Resolved Spectroscopy) technique. Studies have shown:
Reduced cortical GABA levels in alzheimers, correlating with cognitive impairment
Decreased GABA in the [motor cortex[/brain-regions/motor-cortex of ALS patients, predicting disease progression
Altered GABA/glutamate ratios in huntington-pathway striatum
Potential utility of GABA MRS as a pharmacodynamic biomarker for GABAergic therapies in neurodegenerative disease
Microglia](/genes/htt)
[Cryan JF, Kaupmann K. (2021). GABA B receptors in neurodegeneration. Trends in Pharmacological Sciences. PubMed)
[Bhatt DK, et al. (2025). Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer's Disease. Molecular Psychiatry. Full text)
[Huh CYL, Bhatt DK, et al. (2022). Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's Disease. Translational Neurodegeneration, 11, 26. Full text)
[Targa Dias Anastacio H, et al. (2020). Histological characterization of interneurons in Alzheimer's Disease reveals a loss of somatostatin interneurons in the temporal cortex. Neuropathology and Applied Neurobiology. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/32232904/)
[Xu Y, Bhati N, et al. (2020). GABAergic inhibitory interneuron deficits in Alzheimer's Disease: implications for treatment. Frontiers in Neuroscience, 14, 660. [Full text)(https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00660/full)
[Amorim IS, et al. (2023). Factors affecting the GABAergic synapse function in Alzheimer's Disease: Focus on microRNAs. Ageing Research Reviews. [ScienceDirect)(https://www.sciencedirect.com/science/article/pii/S1568163723002829)
[Ali AB, Islam T, Bhatt DK. (2023). The fate of interneurons, GABAA receptor sub-types and perineuronal nets in Alzheimer's Disease. Brain Pathology, 33(4), e13129. Wiley)
The study of Gamma Aminobutyric Acid (Gaba) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Siegel GJ, Agranoff BW, Albers RW, et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects (1999). 1999. ↩︎
Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021). 2021. ↩︎ ↩︎
Schwarcz R, Multiple GABA systems in Alzheimer's Disease brain (2021). 2021. ↩︎ ↩︎
Jo S, et al. Astrocytic GABA release is a novel therapeutic target for Alzheimer's Disease (2014). 2014. ↩︎ ↩︎ ↩︎
Rudolph U, Mohler H, GABA A receptor subtypes: a new pharmacology (2004). 2004. ↩︎ ↩︎
Cryan JF, Kaupmann K, GABA B receptors in neurodegeneration (2021). 2021. ↩︎ ↩︎ ↩︎
Bhatt DK, et al. Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer's Disease (2025). 2025. ↩︎ ↩︎
Huh CYL, Bhatt DK, et al. Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's Disease (2022). 2022. ↩︎ ↩︎
Targa Dias Anastacio H, et al. Histological characterization of interneurons in Alzheimer's Disease reveals a loss of somatostatin interneurons in the temporal cortex (2022). 2022. ↩︎
Palop JJ, Mucke L, Epilepsy and cognitive impairment in Alzheimer's Disease (2010). 2010. ↩︎
Iaccarino HF, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia (2016). 2016. ↩︎
Reiner A, et al. Differential loss of striatal projection neurons in Huntington's Disease (1988). 1988. ↩︎